Ascidian Therapeutics has entered a research partnership and licensing agreement with Roche to discover and develop RNA exon editing therapies to treat neurological diseases. The partnership will ...

June 3 (Reuters) - Ascidian Therapeutics said on Wednesday it has signed a licensing deal for its gene-editing technology with pharma major Eli Lilly (LLY.N), opens new tab, worth up to $1.9 billion, ...

June 18 (Reuters) - Swiss drugmaker Roche (ROG.S), opens new tab will team up with privately held biotech Ascidian Therapeutics to develop gene therapies targeting difficult to treat neurological ...

BOSTON, April 28, 2026 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced it will present two oral presentations and one ...

Eli Lilly LLY2.96%increase; up pointing triangle signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.

BOSTON, June 3, 2026 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced a global research collaboration and licensing ...

Sea squirts are named for a distinguishing feature: a tube that shoots out water as these filter feeders eat. These creatures look like colorful and rubbery blobs in their natural ocean environment, ...

“We can probably edit almost any gene, but that doesn’t mean we should,” Dan Rosan, chief financial and business officer of Ascidian Therapeutics, told Fierce Biotech. That thinking has shaped how the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...